- Home
- PTA vs RGNX Comparison
PTA vs RGNX Comparison
Compare PTA & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PTA | RGNX |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.4M | 793.5M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | PTA | RGNX |
|---|---|---|
| Price | $16.92 | $7.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $23.58 |
| AVG Volume (30 Days) | 301.6K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $16.93 | $5.46 |
| 52 Week High | $20.24 | $16.19 |
Technical Indicators
Market Signals| Indicator | PTA | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 31.90 | 38.53 |
| Support Level | N/A | $5.67 |
| Resistance Level | $19.61 | $7.32 |
| Average True Range (ATR) | 0.28 | 0.45 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 12.50 | 12.92 |
Price Performance
Historical ComparisonAbout PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its main investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.